{ "items": [ "\n\n
\n \n 1 October 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nA RECOVERY Collaborative Group paper has been announced as the 2021 winner of The British Medical Journal\u2019s prestigious UK Research Paper of the Year Award. This award recognises original UK research that has the potential to contribute significantly to improving health and healthcare. The paper, \u201cDexamethasone in Hospitalized Patients with Covid-19\u201d, published in the New England Journal of Medicine, described the discovery in June 2020 of the world\u2019s first effective, readily available treatment for COVID-19 \u2013 the inexpensive steroid, dexamethasone.
\n \n\n\n \n 22 September 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nEvery year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (NDM-CGHR) as second year DPhil student. Our warmest congratulations to you all!
\n \n\n\n \n 21 September 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThere are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.
\n \n\n\n \n 21 September 2021\n \n
\n\n \n\n \n\n \n \n \n \n General\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle\u2019s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include OUCRU in Vietnam and institutions in Canada, Chile, Australia and the UK. GPAS is also now part of the Public Health England New Variant Assessment Platform.
\n \n\n\n \n 14 September 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n KWTRP\n \n \n \n \n MORU\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nFollowing the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor
\n \n\n\n \n 14 September 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nA new, large-scale systematic review published in PLOS Neglected Tropical Diseases has identified clear, significant research gaps in the diagnosis and treatment of Chagas disease. The paper also highlights significant differences in study design, diagnostic methods, duration of follow-up, and the timing of outcome assessment used by investigators even in the last decade.
\n \n\n\n \n 2 September 2021\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n \n \nFor the first time in more than two decades, a team from the KEMRI-Wellcome Trust Research Programme and University of Oxford have quantified the risk of children suffering severe outcomes from malaria - which can have a devastating impact on tens of thousands of children who are admitted to hospital with severe malaria every year.
\n \n\n\n \n 2 September 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford remains top of the table in latest Times Higher Education World University Rankings. In a year dominated by the ongoing Covid-19 pandemic, the rankings reflect the vital role of universities in understanding and managing the crisis as a number of institutions around the world saw significant boosts in their citation scores from Covid-19 focused research.
\n \n\n\n \n 24 August 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Royal Society Africa Prize 2021 is awarded to Professor George Warimwe for his work on zoonoses vaccine development, capacity building in Africa, and his innovative research proposal. This Prize recognises research scientists based in Africa who are making an innovative contribution to the sciences.
\n \n\n\n \n 23 August 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nDespite the limitations and paucity of data, the most comprehensive review of visceral leishmaniasis to date in pregnant women and vertical transmission of leishmaniasis has confirmed that liposomal amphotericin B is the safest treatment option and it is critical to ensure access to this.
\n \n\n\n \n 17 August 2021\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n \n \nA team of KWTRP scientists carried out a major genomic epidemiology of SARS-CoV-2 infections in Kenya during the early phase of the epidemic (March \u2013 July 2020). Researchers provide evidence for at least 35-40 unique introductions of the virus in the coast region \u2013 specifically the epidemic that was largely observed in Mombasa County.
\n \n\n\n \n 30 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n \n \nA 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world\u2019s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.
\n \n\n\n \n 21 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n \n \nAn international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of \u2018fake news\u2019.
\n \n\n\n \n 20 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe RECOVERY Trial has won the Project Management Institute\u2019s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY\u2019s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.
\n \n\n\n \n 19 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nCOVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.
\n \n\n\n \n 9 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n \n \nAs high COVID-19 daily cases and highly transmissible variants risk overwhelming countries\u2019 healthcare systems, COPCOV, the world\u2019s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19
\n \n\n\n \n 8 July 2021\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n \n \nAbout one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.
\n \n\n\n \n 30 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe RECOVERY trial has been jointly awarded Health Data Research UK\u2019s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people\u2019s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O\u2019Shaughnessy at HDR UK\u2019s online Annual Scientific Conference: Data Insights in a Pandemic.
\n \n\n\n \n 22 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nNguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.
\n \n\n\n \n 20 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nA new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.
\n \n\n\n \n 17 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n\n \n\n\n
\n \n\n \n \n \nA trial in infants and toddlers in Burkina Faso showed that experimental malaria vaccine R21/MM confers 77% protection, an unprecedented level and the first malaria vaccine to exceed WHO\u2019s goal of 75% efficacy. While a larger trial is needed to assess its safety and efficacy, R21/MM may substantially reduce child mortality in Sub-Saharan Africa. But this vaccine may be less relevant to Asia Pacific where malaria causes severe morbidity and mortality in all age groups, asymptomatic malaria infections are frequent, and the vaccine may not be effective against P. vivax.
\n \n\n\n \n 16 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.
\n \n\n\n \n 12 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n NDM-CGHR\n \n \n \n \n OUCRU\n \n \n\n \n\n\n
\n \n\n \n \n \nThe pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University\u2019s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.
\n \n\n\n \n 9 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality
\n \n\n\n \n 9 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nCreated in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.
\n \n\n\n \n 8 June 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n \n \nMalaria continues to be a major killer, particularly in sub-Saharan Africa, affecting the world\u2019s most vulnerable populations with more than 500,000 deaths per year, most of them African children. Emergence of resistance to antimalarial drugs is major public health issue. American Society for Microbiology Editor Dr Cesar Arias discusses with Professor Sir Nick White the latest information on this rapidly evolving field.
\n \n\n\n \n 28 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe University of Oxford announces the launch of a centre of global research collaboration and excellence, the Pandemic Sciences Centre. The need for partnership between academic excellence, industry and public health organisations is one of the key lessons learned from the coronavirus pandemic. This centre will unite disciplines, and sectors, to build agile, equitable partnerships that can tackle complex problems and respond to pandemic threats at any time.
\n \n\n\n \n 25 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n
\n \n\n \n \n \nCOVID-19 in Nepal is out of hand and slowly, but surely tracking the infection in India. Although many healthcare workers have been vaccinated throughout the country, the actual vaccination rate is likely very low for the entire country. Buddha Basynat discusses Nepal\u2019s COVID response so far, and why vaccines are an urgent priority.
\n \n\n\n \n 20 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe RECOVERY trial has been named David Sackett Trial of the Year by the Society for Clinical Trials. The award was presented today at the Society for Clinical Trials\u2019 42nd Annual Meeting.
\n \n\n\n \n 19 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n \n \nWhich infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.
\n \n\n\n \n 14 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n
\n \n\n \n \n \nDirector for the Oxford University Clinical Research Unit Nepal, Professor Buddha Basnyat is a medical doctor based in Kathmandu, Nepal. His research interests are infectious diseases and high altitude medicine, and he has almost 300 publications in peer-reviewed medical journals. One of his primary interests is to encourage young people to do clinical research.
\n \n\n\n \n 12 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \n\"Although it is hard to look beyond the pandemic right now,\" says President of the Academy of Medical Sciences Professor Dame Anne Johnson, \"I want to stress how important it is that the Academy Fellowship represents the widest diversity of biomedical and health sciences. The greatest health advances rely on the findings of many types of research, and on multidisciplinary teams and cross-sector and global collaboration.\"
\n \n\n\n \n 7 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nLive and on-line from Bangkok! Be ready for Thursday 13th May, when Pint of Science Thailand will stream live from Bangkok. Join us via Facebook, YouTube or right here from the Pint of Science Thailand website as we journey from bacterial infections to viruses, discover how clinical trials work, and how scientific development is seen in the eyes of the law!
\n \n\n\n \n 5 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n \n \nAlthough improvements in child survival globally have been remarkable, 5.2 million children still died in 2019, over half of these in sub-Saharan Africa. A range of factors likely include disparities in childhood immunisations, supplements and breastfeeding practices, antenatal care, skilled birth attendants working in healthcare facilities. Kenya needs to prioritise its child care plans, based on localities and populations with the greatest need. Two KWTRP studies give granular insights into the situation in regions across Kenya.
\n \n\n\n \n 5 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n
\n \n\n \n \n \nNepal is seeing a COVID surge that is proportionately similar to India. While we try to treat the sick by increasing hospital space and ensuring oxygen supply, we must also plan for an exit strategy. Over-preparation rather than under-preparedness needs to be our mantra, with widespread vaccination the key to get us out of this pandemic, by Professor Buddha Basnyat
\n \n\n\n \n 4 May 2021\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n\n \n\n\n
\n \n\n \n \n \nInterview with KWTRP Malaria immunologist Dr Francis Ndungu. Francis grew up in central Kenya where malaria is not prevalent but is interested in understanding of how semi-immune individuals control malaria parasite growth and the associated inflammation symptoms. His current work is in understanding how we develop immunity to Malaria. He is also interested in the potential translation of that knowledge in the development of effective malaria vaccines.
\n \n\n\n \n 27 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n KWTRP\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nThe International Girl\u2019s in ICT day is commemorated to create awareness on the critical need for more girls and women in the ICT sector, encourage and inspire young girls to actively pursue careers in STEM as well as engage the community to promote collaboration through partnerships. Kathreen Wafula, an ICT Support Technician in Kilifi, joins a strong team of techies and is one of the 4 women in the department.
\n \n\n\n \n 26 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nWorld Immunization Week highlights the role vaccinations play in improving the health of communities. As the COVID pandemic continues to impact countries worldwide, governments are facing challenges related to coverage, equity and sustainability of routine immunisation alongside access and the particular maintenance requirements related to the SARS-CoV-2 vaccines. Communication with communities has been key to ensure continued engagement with the vaccine programs despite the challenges of current contexts.
\n \n\n\n \n 25 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n Public Engagement\n \n \n\n \n\n\n
\n \n\n \n \n \nFor World Malaria Day 2021, F1000 Research Blog spoke to Professor Phaik Yeong Cheah about her research focussed on drama and arts-based community engagement for malaria research, published with Wellcome Open Research.
\n \n\n\n \n 23 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n\n \n\n\n
\n \n\n \n \n \nOn Sunday 25 April, World Malaria Day, the Developing Paediatric Primaquine (DPP) project will launch its website. DPP will produce children-appropriate primaquine doses that could both cut malaria deaths in vulnerable African children by blocking transmission of P. falciparum malaria and reduce P. vivax malaria more widely.
\n \n\n\n \n 21 April 2021\n \n
\n\n \n\n \n\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n\n \n\n\n
\n \n\n \n \n \nAnuraj Shankar from our EOCRU unit in Jakarta, Indonesia, with Elizabeth Prado and Leila Larson describe a meta-analysis showing that responsive caregiving boosts infants\u2019 brain development. Parenting group sessions and home visits improve cognitive, language, and motor skills. And nutrition-only programmes have much less effect than comprehensive interventions.
\n \n\n\n \n 30 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThis large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.
\n \n\n\n \n 24 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n General\n \n \n\n \n\n\n
\n \n\n \n \n \nEvery year, over a million children fall ill with tuberculosis (TB) globally, and about a quarter die from this potentially preventable and curable disease. The main challenge remains the diagnosis of TB, especially in resource-constrained settings. We currently need to collect mucus from the lungs or liquid contents of the stomach, which must be collected in a hospital. Different ways to diagnosis TB in children are urgently needed, especially for those infected with HIV. An international collaboration is now conducting a large diagnostic study in Uganda to fill this gap. The study aims to detect TB bacteria in body fluids such as blood, urine, stool and saliva that are easier to collect.
\n \n\n\n \n 23 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.
\n \n\n\n \n 19 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nMillions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network\u2019s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.
\n \n\n\n \n 17 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nResearchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.
\n \n\n\n \n 16 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n MORU\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.
\n \n\n\n \n 5 March 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nEstablished to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms \u2013 aspirin, baricitinib, Regeneron\u2019s antibody cocktail, and dimethyl fumarate \u2013 continues as planned.
\n \n\n\n \n 22 February 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n \n \n OUCRU\n \n \n \n \n OUCRU-Indonesia\n \n \n \n \n OUCRU-Nepal\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world\u2019s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.
\n \n\n\n \n 12 February 2021\n \n
\n\n \n\n \n\n \n \n \n \n NDM-CGHR\n \n \n\n \n\n\n
\n \n\n \n \n \nThe Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that tocilizumab, an anti-inflammatory treatment, reduces the risk of death when given to hospitalised patients with severe COVID-19. The study also showed that tocilizumab shortens the time until patients are successfully discharged from hospital and reduces the need for a mechanical ventilator.
\n \n\n